Guggenheim analyst Michael Schmidt noted that Roche (RHHBY) announced it is voluntarily withdrawing Tecentriq for the treatment of patients with first-line metastatic bladder cancer who are not eligible for cisplatin with PD-L1 positive tumors, or who are not eligible for any platinum-based chemotherapies regardless of PD-L1 status after Imvigor130 failed to meet the co-primary endpoint of overall survival in the final analysis. Given today’s news, platinum doublets without addition of checkpoint inhibitors remain the standard of care for first-line mBC patients, said Schmidt, who thinks this bodes well for the regulatory review of Seagen’s (SGEN) Cohort K data seeking accelerated FDA-approval in cis-ineligible first-line mBC with an FDA decision anticipated in mid-2023. He keeps a Buy rating on Seagen shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SGEN:
Source
